Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | AR | P10275 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5562070 | 0.91 | KMT2A (0.50) | SMN1; SMN2ARMEN1KMT2ACYP1A2 | |
| SCHEMBL5557165 | 0.87 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL25312862 | 0.84 | SMN1; SMN2 (0.56) | SMN1; SMN2ALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL6434084 | 0.83 | SMN1; SMN2 (0.49) | SMN1; SMN2ARALDH1A1MEN1KMT2A | |
| SCHEMBL1130860 | 0.83 | SMN1; SMN2 (0.66) | SMN1; SMN2ALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL25312928 | 0.82 | SMN1; SMN2 (0.54) | SMN1; SMN2ARMEN1KMT2ACYP1A2 | |
| SCHEMBL28526955 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2ALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL5559850 | 0.81 | CYP1A2 (0.45) | SMN1; SMN2ALDH1A1MEN1KMT2ACYP1A2 | |
| SCHEMBL5563504 | 0.81 | AAK1 (0.41) | AR | |
| SCHEMBL6166451 | 0.80 | CYP1A2 (0.37) | ARALDH1A1MEN1KMT2ACYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474416-B1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | HOFFMANN LA ROCHE (CH) | 2007-09-26 | — | — | EP | disclosed |
| US-6949542-B2 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | HOFFMAN-LA ROCHE INC. (US) | 2005-09-27 | — | — | US | disclosed |
| EP-1474416-A1 | DIHYDROBENZODIAZEPIN-2-ONE-DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | F. HOFFMAN-LA ROCHE AG (CH) | 2003-09-04 | — | — | US | disclosed |
| WO-2003066623-A1 | DIHYDROBENZODIAZEPIN-2-ONE DERIVATIVES FOR THE TREATMENT OF NEUROLOGICAL DISORDERS | F. HOFFMANN-LA ROCHE AG (CH) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166639-A1 | Dihydro-benzo[b][1,4]diazepin-2-one derivatives | CYP1B1, GRIN2B, CYP4B1 | SMN1; SMN2 538/4885AR 2285/4885ALDH1A1 314/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.